Peptide Therapy
Individual consultation required.
Your provider will review your individual circumstances and discuss whether a specific option is appropriate. Ask about the evidence, product source, regulatory status, risks and alternatives before deciding whether to proceed.
How we practice peptide therapy.
Call the office for an individual consultation. The practice will discuss the proposed product and any required evaluation before treatment.
Compounded drugs are not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed. A pharmacy registration or a prescription does not make a compounded product FDA-approved.
Questions to discuss.
Evidence
Ask about evidence for the specific product and intended use.
Regulatory status
Ask whether the specific product is FDA-approved and whether the proposed use is within its approved labeling.
Risks and alternatives
Discuss potential harms, alternatives and the option of no treatment.
Follow-up
Ask how your provider will monitor your care if treatment is recommended.
Who this helps.
- An individual conversation about available options
- Questions about risks, evidence and alternatives
- Patients with active cancer
- Anyone seeking peptides without a baseline workup
- Patients in WADA-tested sport without explicit awareness of governance rules
Product-specific evidence and regulatory status should be discussed with your provider. Results are not guaranteed.
Common questions.
Pairs well with these.
Ready to talk about peptide therapy?
First visits are unhurried. Your provider walks you through your labs, options, and a plan you can sustain.